Skip to main content

Sweden

06
Aug 2021

TLV assessed Oncotype DX and ProSigna tests for early breast cancer detection in July 2021

In July 2021, the Dental and Pharmaceutical Benefits Agency released two completed health economic evaluations on the cost-effectiveness of the Oncotype DX and ProSigna tests. The evaluation was performed at the request of the Medical Technology Product (MTP) Council. The cost per quality-adjusted life-years for ProSigna is estimated to be 207,000 SEK compared to the stand-alone clinical pathology assessment. The analysis indicates that the use of Oncotype DX provides greater benefit than the alternative, also at a lower cost.
19
Apr 2021

Swedish MTP Council will evaluate more technologies for self-monitoring of atrial fibrillation

On April 09, 2021, the Swedish Medical Technologies Product (MTP) Council decided to add more technologies to the ongoing evaluation for self-monitoring of atrial fibrillation within the Orderly introduction framework, initiated in December 2020. MTP Council commissioned the Dental and Pharmaceutical Benefits Agency (TLV) to perform a health-economic evaluation of five products (Coala, KardiaMobile, CardioMem CM 100 XT, PhysioMem PM 100, Zenicor). MTP Council will then make recommendations to the regions on whether to adopt these technologies or not.
04
Mar 2021

Ongoing health technology assessments by the Swedish SBU

The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) systematically evaluates healthcare technologies and practices from medical, economic, ethical, and social standpoints. Currently, the SBU is working on assessments of treatment methods of gastrointestinal conditions, musculoskeletal disorders, pain treatment, medical aids, e-health technologies, and other topics.
06
Jan 2021

Swedish MTP Council has decided to evaluate two new technologies for self-monitoring of atrial fibrillation

In December 2020, Swedish Medical Technologies Product (MTP) Council decided to evaluate new technologies for self-monitoring of atrial fibrillation within the Orderly introduction framework. MTP Council commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to perform a health-economic evaluation of Coala Heart Monitor Pro and KardiaMobile; however, other products may also be considered later.
18
Dec 2020

A new chapter for vascular surgery procedures will be introduced to the Swedish Classification of Health Care Measures from January 2021

In early December 2020, the Swedish National Board of Health and Welfare announced significant changes in the Swedish Classification of Health Care Measures (KVÅ) structure related to vascular surgery procedure codes. New Chapter V, “Operations on the aorta, peripheral vessels and lymphatic system,” will be introduced from January 2021, gathering all vascular surgical procedures previously located in several subchapters.
14
Dec 2020

Future management of healthcare in the Swedish Stockholm Region

In November 2020, Stockholm Region issued a preliminary version of the prospective report for the management of health care up to 2040. The report raised the need for new ways of organizing health care in the Stockholm Region and outlined the increase of standardization and alignment trend, emerge of collaborative governance models, the increase of care structure complexity, etc.
10
Dec 2020

Swedish TLV report on its activities in health economic evaluations of medical technologies in 2020

On December 03, 2020, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) published a report on its activities in health economic evaluations of medical technologies in 2020. The significant change is that since 2020 TLV has a permanent assignment to carry out horizon scanning and health economic evaluations of medical technology products as a part of the national orderly introduction framework.